Iraqi Registry Data Proves Safety and Efficacy of Switching to Adalimumab Biosimilar in Treating Rheumatoid Arthritis |
 |
| ياسمين عباس حمادي |
| Authors : Yasameen Abbas Humadi1*\r\n, Nabaa Ihsan2\r\n, Asal Adnan3\r\n, Marwa Moayad4\r\n, Ali AlKazzaz5\r\n, Avin Maroof6\r\n, Ali \r\nAbdulrahman7\r\n, Nazar Abdulateef3\r\n, Mohammad AlOsami3\r\n, Faiq Gorial3\r\n, Mohammed Altahhan2\r\n, Zahraa Almansi2\r\n, Ali \r\nAlNoori2 |
Background: Adalimumab is approved for Rheumatoid Arthritis (RA). In 2021, A biosimilar \r\n(ABP501; Amgevita®) was licensed in Iraq. The current study aimed to ensure the safety and \r\nEfficacy of Amgevita-Adalimumab biosimilar- in RA Patients in Iraq.\r\nSubjects and Methods: A Prospective Observational Study Started on 69 RA Records \r\nReceiving Amgevita. Data collected from the local registry was then examined for disease \r\nactivity and adverse reactions for 9 months follow-up.\r\nResults: Thirty patients completed the 9 months of the study: aged (49±14) years; 77.5% \r\nfemales. After 3, 6, and 9 months of follow-up, patients\' mean ± (SD) Clinical Disease Activity \r\nIndex (CDAI) was 27.8 (13.60) which was statistically lower (19.80) (6.96), 17.70 (2.790), and \r\n19 (1.040), p
(FULL ARTICLE LINK) Read more ...
1-12-2024
|
|
|